PROTEOMICS INTERNATIONAL LABORATORIES LTD - Announcements

0.00%

38.0¢

Market Cap $62.19M

Healthcare Biotechnology

Proteomics International Laboratories Ltd is an Australia-based medical technology... Proteomics International Laboratories Ltd is an Australia-based medical technology company. The Company is engaged in predictive diagnostics and bioanalytical services. It specializes in the area of proteomics, the industrial scale study of the structure and function of proteins. It focuses on developing and commercializing diagnostic tests for chronic diseases. Its principal activities fall into three key areas: commercialization of PromarkerD, the predictive test for diabetic kidney disease (DKD) and future kidney function decline in patients with type 2 diabetes; precision diagnostic tests in development: the Promarker pipeline, and specialist accredited analytical services on a commercial basis. Its Promarker pipeline and analytical services include PromarkerEndo, PromarkerEso and OxiDx technology. PromarkerEndo is a prototype diagnostic test for endometriosis identified up to 90% of patients with the disease. PromarkerEso is a prototype diagnostic test for esophageal cancer.More

Corporate Spotlight
Not Yet Available

Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.

Claim your IR profile

See benefits

Announcements

Filter Results

All Price Sensitive Only

PIQ	Exercise of Director Options		24/10/22	208.11KB	Share
PIQ	Application for quotation of securities - PIQ		24/10/22	24.98KB	Share
PIQ	Precision diagnostics facility receives $2m funding boost	PRICE SENSITIVE	20/10/22	169.39KB	Share
PIQ	Notice of Annual General Meeting/Proxy Form		19/10/22	2.09MB	Share
PIQ	Proteomics receives $1.7 million in R&D tax incentive	PRICE SENSITIVE	17/10/22	124.5KB	Share
PIQ	Notification of cessation of securities - PIQ		14/10/22	22.31KB	Share
PIQ	New Oesophageal Cancer Diagnostic shows strong performance	PRICE SENSITIVE	27/09/22	1.05MB	Share
PIQ	Annual Report to shareholders		30/08/22	6.86MB	Share
PIQ	Preliminary Final Report	PRICE SENSITIVE	30/08/22	297.21KB	Share
PIQ	Corporate Governance Statement and Appendix 4G		30/08/22	527.38KB	Share
PIQ	OxiDx launched to maximise oxidative stress technology	PRICE SENSITIVE	29/08/22	151.06KB	Share
PIQ	Change in substantial holding - Lipscombe		23/08/22	116.71KB	Share
PIQ	Completion of Placement and Exercise of Performance Rights	PRICE SENSITIVE	22/08/22	213.43KB	Share
PIQ	Application for quotation of securities - PIQ		22/08/22	29.87KB	Share
PIQ	Application for quotation of securities - PIQ		22/08/22	25.04KB	Share
PIQ	Proposed issue of securities - PIQ		15/08/22	27.22KB	Share
PIQ	Proteomics raises $8m in highly successful Placement	PRICE SENSITIVE	15/08/22	256.76KB	Share
PIQ	Trading Halt	PRICE SENSITIVE	11/08/22	636KB	Share
PIQ	Reinstatement to Quotation	PRICE SENSITIVE	09/08/22	408.62KB	Share
PIQ	Proteomics signs binding LOI with Sonic Healthcare USA	PRICE SENSITIVE	09/08/22	155.17KB	Share
PIQ	Suspension from Quotation	PRICE SENSITIVE	08/08/22	441.61KB	Share
PIQ	Trading Halt	PRICE SENSITIVE	04/08/22	637.55KB	Share
PIQ	Clinical Utility Study demonstrates PromarkerD test benefits	PRICE SENSITIVE	02/08/22	167.33KB	Share
PIQ	Potential breakthrough blood test for endometriosis	PRICE SENSITIVE	01/08/22	918.29KB	Share
PIQ	June 2022 Quarterly Activities Report and Appendix 4C	PRICE SENSITIVE	28/07/22	720.69KB	Share
PIQ	European PromarkerD patents expanded beyond diabetes	PRICE SENSITIVE	25/07/22	156.32KB	Share
PIQ	Investor Presentation		18/07/22	1.42MB	Share
PIQ	Exercise of Performance Rights		11/07/22	207.45KB	Share
PIQ	Application for quotation of securities - PIQ		11/07/22	25.07KB	Share
PIQ	Endometriosis clinical validation study readout positive	PRICE SENSITIVE	30/06/22	159.93KB	Share
PIQ	Proteomics secures licence to oesophageal cancer biomarkers	PRICE SENSITIVE	21/06/22	249.11KB	Share
PIQ	PromarkerD manufacturing tech-transfer completed	PRICE SENSITIVE	16/06/22	152.69KB	Share
PIQ	Study shows PromarkerD also predicts late-stage renal issues		06/06/22	487.68KB	Share
PIQ	PromarkerD registration submitted to the TGA		02/06/22	143.86KB	Share
PIQ	Investor Presentation - Jefferies MedTech & Biotech summit		26/05/22	1.39MB	Share
PIQ	Proteomics awarded $400,000 funding to support manufacturing	PRICE SENSITIVE	12/05/22	158.04KB	Share
PIQ	March 2022 Quarterly Activities Report and Appendix 4C	PRICE SENSITIVE	28/04/22	429.48KB	Share
PIQ	New Clinical Advisory Board for PromarkerD global rollout	PRICE SENSITIVE	12/04/22	155.62KB	Share
PIQ	Investor Presentation		07/04/22	1.32MB	Share
PIQ	PromarkerD patent granted in India		24/03/22	889.96KB	Share
PIQ	Investor Presentation		10/03/22	1.41MB	Share
PIQ	Appendix 4D and Interim Financial Report	PRICE SENSITIVE	24/02/22	572.1KB	Share
PIQ	PromarkerD completes 'pre-assessment' for Medicare rebate	PRICE SENSITIVE	22/02/22	152.17KB	Share
PIQ	Exercise of Options		11/02/22	207.6KB	Share
PIQ	Application for quotation of securities - PIQ		11/02/22	24.96KB	Share
PIQ	Proteomics identifies novel biomarkers for Asthma and COPD		07/02/22	778.31KB	Share
PIQ	Unique panel of biomarkers identified for oesophageal cancer	PRICE SENSITIVE	04/02/22	780.78KB	Share
PIQ	December 2021 Quarterly Activities Report and Appendix 4C	PRICE SENSITIVE	27/01/22	605.78KB	Share
PIQ	Change of Registry Address		20/12/21	152.9KB	Share
PIQ	Proteomics secures major pharmacokinetic testing contract	PRICE SENSITIVE	16/12/21	151.09KB	Share
PIQ	Proteomics receives $1.2 million in R&D tax incentive	PRICE SENSITIVE	14/12/21	124.46KB	Share
PIQ	Notification regarding unquoted securities - PIQ		13/12/21	25.85KB	Share
PIQ	Issue of Equity Incentives to Employees		13/12/21	412.49KB	Share
PIQ	Final Director's Interest Notice		25/11/21	107.09KB	Share
PIQ	Results of Annual General Meeting		25/11/21	267.46KB	Share
PIQ	AGM Chairman's Address and Investor Presentation	PRICE SENSITIVE	25/11/21	1.42MB	Share
PIQ	FDA advises regulatory pathway for PromarkerD in US		24/11/21	151.4KB	Share
PIQ	PromarkerD distribution network expands to Britain	PRICE SENSITIVE	23/11/21	169.07KB	Share
PIQ	Initial Directors' Interest Notices		16/11/21	229.06KB	Share
PIQ	Proposed issue of securities - PIQ		16/11/21	30.84KB	Share
PIQ	Director appointments		16/11/21	233.94KB	Share
PIQ	PromarkerD outperforms standard of care tests for DKD	PRICE SENSITIVE	05/11/21	755.17KB	Share
PIQ	Change of Directors' Interest Notices		04/11/21	335.87KB	Share
PIQ	Exercise of Director Options		04/11/21	208.27KB	Share
PIQ	Application for quotation of securities - PIQ		04/11/21	24.94KB	Share
PIQ	Proteomics awarded $100,000 manufacturing funding	PRICE SENSITIVE	03/11/21	161.36KB	Share
PIQ	Jobkeeper Payments Notification		29/10/21	348.44KB	Share
PIQ	September 2021 Quarterly Activities Report and Appendix 4C	PRICE SENSITIVE	28/10/21	686.2KB	Share
PIQ	Notice of Annual General Meeting/Proxy Form		26/10/21	1.86MB	Share
PIQ	Proteomics Chairman Terry Sweet to retire at 2021 AGM		26/10/21	136.05KB	Share
PIQ	Clinical utility study shows benefit of PromarkerD testing	PRICE SENSITIVE	18/10/21	486.39KB	Share
PIQ	Annual Report to shareholders		30/08/21	4.56MB	Share
PIQ	Preliminary Final Report	PRICE SENSITIVE	30/08/21	337.96KB	Share
PIQ	Corporate Governance Statement and Appendix 4G		30/08/21	529.08KB	Share
PIQ	Proteomics contracts Biotem to manufacture PromarkerD kits	PRICE SENSITIVE	12/08/21	159KB	Share
PIQ	Conference presentation - Australasian Diabetes Congress 202		11/08/21	684.12KB	Share
PIQ	Proteomics to collaborate to validate test for endometriosis	PRICE SENSITIVE	04/08/21	330.37KB	Share
PIQ	Application for quotation of securities - PIQ		02/08/21	24.92KB	Share
PIQ	Exercise of Options and Secondary Trading Notice		02/08/21	207.98KB	Share
PIQ	June 2021 Quarterly Activities Report and Appendix 4C	PRICE SENSITIVE	30/07/21	482.43KB	Share
PIQ	Manufacturing update and clarification of Abcam engagement		28/07/21	576.22KB	Share
PIQ	Proteomics engages Abcam to manufacture PromarkerD reagents	PRICE SENSITIVE	22/07/21	246.64KB	Share
PIQ	Notification regarding unquoted securities - PIQ		20/07/21	39.22KB	Share
PIQ	Issue of Equity Incentives to Key Management Personnel		20/07/21	792.15KB	Share
PIQ	Investor Presentation - non-deal roadshow		20/07/21	1.42MB	Share
PIQ	Study shows diabetes drug improves PromarkerD risk scores	PRICE SENSITIVE	16/07/21	304.01KB	Share
PIQ	Trading Halt	PRICE SENSITIVE	14/07/21	311.5KB	Share
PIQ	Pause in Trading	PRICE SENSITIVE	14/07/21	116.18KB	Share
PIQ	Reinstatement to Official Quotation	PRICE SENSITIVE	02/07/21	408.34KB	Share
PIQ	Update on study presented at ADA Conference	PRICE SENSITIVE	02/07/21	216.86KB	Share
PIQ	Request for extension of voluntary suspension		02/07/21	226.97KB	Share
PIQ	Suspension from Official Quotation	PRICE SENSITIVE	29/06/21	639.99KB	Share
PIQ	Trading Halt	PRICE SENSITIVE	25/06/21	309.34KB	Share
PIQ	Pause in Trading	PRICE SENSITIVE	25/06/21	116.56KB	Share
PIQ	Modelling shows PromarkerD could save US payers $384 billion	PRICE SENSITIVE	25/06/21	249.35KB	Share
PIQ	Proteomics bolsters executive team - CCO and CFO appointed		10/06/21	237.95KB	Share
PIQ	Proteomics secures major analytical services contract	PRICE SENSITIVE	18/05/21	245.28KB	Share
PIQ	Major economic health benefit demonstrated for PromarkerD	PRICE SENSITIVE	13/05/21	250.44KB	Share
PIQ	Proposed issue of Securities - PIQ		30/04/21	26.61KB	Share
PIQ	Issue of Options and Secondary Trading Notice		30/04/21	402.24KB	Share

PIQ Exercise of Director Options
24/10/22		208.11KB	Share
PIQ Application for quotation of securities - PIQ
24/10/22		24.98KB	Share
PIQ Precision diagnostics facility receives $2m funding boost
20/10/22	PRICE SENSITIVE	169.39KB	Share
PIQ Notice of Annual General Meeting/Proxy Form
19/10/22		2.09MB	Share
PIQ Proteomics receives $1.7 million in R&D tax incentive
17/10/22	PRICE SENSITIVE	124.5KB	Share
PIQ Notification of cessation of securities - PIQ
14/10/22		22.31KB	Share
PIQ New Oesophageal Cancer Diagnostic shows strong performance
27/09/22	PRICE SENSITIVE	1.05MB	Share
PIQ Annual Report to shareholders
30/08/22		6.86MB	Share
PIQ Preliminary Final Report
30/08/22	PRICE SENSITIVE	297.21KB	Share
PIQ Corporate Governance Statement and Appendix 4G
30/08/22		527.38KB	Share
PIQ OxiDx launched to maximise oxidative stress technology
29/08/22	PRICE SENSITIVE	151.06KB	Share
PIQ Change in substantial holding - Lipscombe
23/08/22		116.71KB	Share
PIQ Completion of Placement and Exercise of Performance Rights
22/08/22	PRICE SENSITIVE	213.43KB	Share
PIQ Application for quotation of securities - PIQ
22/08/22		29.87KB	Share
PIQ Application for quotation of securities - PIQ
22/08/22		25.04KB	Share
PIQ Proposed issue of securities - PIQ
15/08/22		27.22KB	Share
PIQ Proteomics raises $8m in highly successful Placement
15/08/22	PRICE SENSITIVE	256.76KB	Share
PIQ Trading Halt
11/08/22	PRICE SENSITIVE	636KB	Share
PIQ Reinstatement to Quotation
09/08/22	PRICE SENSITIVE	408.62KB	Share
PIQ Proteomics signs binding LOI with Sonic Healthcare USA
09/08/22	PRICE SENSITIVE	155.17KB	Share
PIQ Suspension from Quotation
08/08/22	PRICE SENSITIVE	441.61KB	Share
PIQ Trading Halt
04/08/22	PRICE SENSITIVE	637.55KB	Share
PIQ Clinical Utility Study demonstrates PromarkerD test benefits
02/08/22	PRICE SENSITIVE	167.33KB	Share
PIQ Potential breakthrough blood test for endometriosis
01/08/22	PRICE SENSITIVE	918.29KB	Share
PIQ June 2022 Quarterly Activities Report and Appendix 4C
28/07/22	PRICE SENSITIVE	720.69KB	Share
PIQ European PromarkerD patents expanded beyond diabetes
25/07/22	PRICE SENSITIVE	156.32KB	Share
PIQ Investor Presentation
18/07/22		1.42MB	Share
PIQ Exercise of Performance Rights
11/07/22		207.45KB	Share
PIQ Application for quotation of securities - PIQ
11/07/22		25.07KB	Share
PIQ Endometriosis clinical validation study readout positive
30/06/22	PRICE SENSITIVE	159.93KB	Share
PIQ Proteomics secures licence to oesophageal cancer biomarkers
21/06/22	PRICE SENSITIVE	249.11KB	Share
PIQ PromarkerD manufacturing tech-transfer completed
16/06/22	PRICE SENSITIVE	152.69KB	Share
PIQ Study shows PromarkerD also predicts late-stage renal issues
06/06/22		487.68KB	Share
PIQ PromarkerD registration submitted to the TGA
02/06/22		143.86KB	Share
PIQ Investor Presentation - Jefferies MedTech & Biotech summit
26/05/22		1.39MB	Share
PIQ Proteomics awarded $400,000 funding to support manufacturing
12/05/22	PRICE SENSITIVE	158.04KB	Share
PIQ March 2022 Quarterly Activities Report and Appendix 4C
28/04/22	PRICE SENSITIVE	429.48KB	Share
PIQ New Clinical Advisory Board for PromarkerD global rollout
12/04/22	PRICE SENSITIVE	155.62KB	Share
PIQ Investor Presentation
07/04/22		1.32MB	Share
PIQ PromarkerD patent granted in India
24/03/22		889.96KB	Share
PIQ Investor Presentation
10/03/22		1.41MB	Share
PIQ Appendix 4D and Interim Financial Report
24/02/22	PRICE SENSITIVE	572.1KB	Share
PIQ PromarkerD completes 'pre-assessment' for Medicare rebate
22/02/22	PRICE SENSITIVE	152.17KB	Share
PIQ Exercise of Options
11/02/22		207.6KB	Share
PIQ Application for quotation of securities - PIQ
11/02/22		24.96KB	Share
PIQ Proteomics identifies novel biomarkers for Asthma and COPD
07/02/22		778.31KB	Share
PIQ Unique panel of biomarkers identified for oesophageal cancer
04/02/22	PRICE SENSITIVE	780.78KB	Share
PIQ December 2021 Quarterly Activities Report and Appendix 4C
27/01/22	PRICE SENSITIVE	605.78KB	Share
PIQ Change of Registry Address
20/12/21		152.9KB	Share
PIQ Proteomics secures major pharmacokinetic testing contract
16/12/21	PRICE SENSITIVE	151.09KB	Share
PIQ Proteomics receives $1.2 million in R&D tax incentive
14/12/21	PRICE SENSITIVE	124.46KB	Share
PIQ Notification regarding unquoted securities - PIQ
13/12/21		25.85KB	Share
PIQ Issue of Equity Incentives to Employees
13/12/21		412.49KB	Share
PIQ Final Director's Interest Notice
25/11/21		107.09KB	Share
PIQ Results of Annual General Meeting
25/11/21		267.46KB	Share
PIQ AGM Chairman's Address and Investor Presentation
25/11/21	PRICE SENSITIVE	1.42MB	Share
PIQ FDA advises regulatory pathway for PromarkerD in US
24/11/21		151.4KB	Share
PIQ PromarkerD distribution network expands to Britain
23/11/21	PRICE SENSITIVE	169.07KB	Share
PIQ Initial Directors' Interest Notices
16/11/21		229.06KB	Share
PIQ Proposed issue of securities - PIQ
16/11/21		30.84KB	Share
PIQ Director appointments
16/11/21		233.94KB	Share
PIQ PromarkerD outperforms standard of care tests for DKD
05/11/21	PRICE SENSITIVE	755.17KB	Share
PIQ Change of Directors' Interest Notices
04/11/21		335.87KB	Share
PIQ Exercise of Director Options
04/11/21		208.27KB	Share
PIQ Application for quotation of securities - PIQ
04/11/21		24.94KB	Share
PIQ Proteomics awarded $100,000 manufacturing funding
03/11/21	PRICE SENSITIVE	161.36KB	Share
PIQ Jobkeeper Payments Notification
29/10/21		348.44KB	Share
PIQ September 2021 Quarterly Activities Report and Appendix 4C
28/10/21	PRICE SENSITIVE	686.2KB	Share
PIQ Notice of Annual General Meeting/Proxy Form
26/10/21		1.86MB	Share
PIQ Proteomics Chairman Terry Sweet to retire at 2021 AGM
26/10/21		136.05KB	Share
PIQ Clinical utility study shows benefit of PromarkerD testing
18/10/21	PRICE SENSITIVE	486.39KB	Share
PIQ Annual Report to shareholders
30/08/21		4.56MB	Share
PIQ Preliminary Final Report
30/08/21	PRICE SENSITIVE	337.96KB	Share
PIQ Corporate Governance Statement and Appendix 4G
30/08/21		529.08KB	Share
PIQ Proteomics contracts Biotem to manufacture PromarkerD kits
12/08/21	PRICE SENSITIVE	159KB	Share
PIQ Conference presentation - Australasian Diabetes Congress 202
11/08/21		684.12KB	Share
PIQ Proteomics to collaborate to validate test for endometriosis
04/08/21	PRICE SENSITIVE	330.37KB	Share
PIQ Application for quotation of securities - PIQ
02/08/21		24.92KB	Share
PIQ Exercise of Options and Secondary Trading Notice
02/08/21		207.98KB	Share
PIQ June 2021 Quarterly Activities Report and Appendix 4C
30/07/21	PRICE SENSITIVE	482.43KB	Share
PIQ Manufacturing update and clarification of Abcam engagement
28/07/21		576.22KB	Share
PIQ Proteomics engages Abcam to manufacture PromarkerD reagents
22/07/21	PRICE SENSITIVE	246.64KB	Share
PIQ Notification regarding unquoted securities - PIQ
20/07/21		39.22KB	Share
PIQ Issue of Equity Incentives to Key Management Personnel
20/07/21		792.15KB	Share
PIQ Investor Presentation - non-deal roadshow
20/07/21		1.42MB	Share
PIQ Study shows diabetes drug improves PromarkerD risk scores
16/07/21	PRICE SENSITIVE	304.01KB	Share
PIQ Trading Halt
14/07/21	PRICE SENSITIVE	311.5KB	Share
PIQ Pause in Trading
14/07/21	PRICE SENSITIVE	116.18KB	Share
PIQ Reinstatement to Official Quotation
02/07/21	PRICE SENSITIVE	408.34KB	Share
PIQ Update on study presented at ADA Conference
02/07/21	PRICE SENSITIVE	216.86KB	Share
PIQ Request for extension of voluntary suspension
02/07/21		226.97KB	Share
PIQ Suspension from Official Quotation
29/06/21	PRICE SENSITIVE	639.99KB	Share
PIQ Trading Halt
25/06/21	PRICE SENSITIVE	309.34KB	Share
PIQ Pause in Trading
25/06/21	PRICE SENSITIVE	116.56KB	Share
PIQ Modelling shows PromarkerD could save US payers $384 billion
25/06/21	PRICE SENSITIVE	249.35KB	Share
PIQ Proteomics bolsters executive team - CCO and CFO appointed
10/06/21		237.95KB	Share
PIQ Proteomics secures major analytical services contract
18/05/21	PRICE SENSITIVE	245.28KB	Share
PIQ Major economic health benefit demonstrated for PromarkerD
13/05/21	PRICE SENSITIVE	250.44KB	Share
PIQ Proposed issue of Securities - PIQ
30/04/21		26.61KB	Share
PIQ Issue of Options and Secondary Trading Notice
30/04/21		402.24KB	Share

REFRESH

First 2 3 4 5 6

Add to My Watchlist

What is My Watchlist?

A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.

(20min delay)
Last 38.0¢		Change 0.000(0.00%)		Mkt cap ! $62.19M

Open	High	Low	Value	Volume
39.0¢	40.0¢	38.0¢	$58.62K	150.4K

Buyers (Bids)

No.	Vol.	Price($)
2	12180	37.0¢

Sellers (Offers)

Price($)	Vol.	No.
38.5¢	5203	1

View Market Depth

No.	Vol.	Price($)
2	12180	0.370
1	36	0.360
2	31937	0.355
2	6428	0.350
1	2898	0.345

Price($)	Vol.	No.
0.385	5203	1
0.400	26318	4
0.410	100000	1
0.425	2775	1
0.440	1983	1

Last trade - 15.42pm 08/08/2025 (20 minute delay)

PIQ (ASX) Chart

PROTEOMICS INTERNATIONAL LABORATORIES LTD - Announcements

Corporate SpotlightNot Yet Available

Announcements

Buyers (Bids)

Sellers (Offers)

Top Stories

Corporate Spotlight
Not Yet Available